Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Neurochem Res ; 49(9): 2440-2452, 2024 Sep.
Article in English | MEDLINE | ID: mdl-38847910

ABSTRACT

Parkinson's disease (PD) is a complex multifactorial progressive neurodegenerative disease characterized by locomotor alteration due to the specific deterioration of dopaminergic (DAergic) neurons in the substantia nigra pars compacta (SNpc). Mounting evidence shows that human LRRK2 (hLRRK2) kinase activity is involved in oxidative stress (OS)-induced neurodegeneration, suggesting LRRK2 inhibition as a potential therapeutic target. We report that the hLRRK2 inhibitor PF-06447475 (PF-475) prolonged lifespan, increased locomotor activity, maintained DAergic neuronal integrity, and reduced lipid peroxidation (LPO) in female Drosophila melanogaster flies chronically exposed to paraquat (PQ), a redox cycling compound, compared to flies treated with vehicle only. Since LRRK2 is an evolutionary conserved kinase, the present findings reinforce the idea that either reduction or inhibition of the LRRK2 kinase might decrease OS and locomotor alterations associated with PD. Our observations highlight the importance of uncovering the function of the hLRRK2 orthologue dLrrk2 in D. melanogaster as an excellent model for pharmacological screenings.


Subject(s)
Drosophila Proteins , Drosophila melanogaster , Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 , Locomotion , Longevity , Oxidative Stress , Paraquat , Animals , Oxidative Stress/drug effects , Leucine-Rich Repeat Serine-Threonine Protein Kinase-2/antagonists & inhibitors , Leucine-Rich Repeat Serine-Threonine Protein Kinase-2/metabolism , Paraquat/toxicity , Longevity/drug effects , Locomotion/drug effects , Female , Drosophila Proteins/metabolism , Drosophila Proteins/antagonists & inhibitors , Protein Kinase Inhibitors/pharmacology , Herbicides/toxicity
2.
Brain Res ; 1657: 253-261, 2017 02 15.
Article in English | MEDLINE | ID: mdl-28041945

ABSTRACT

Leucine-rich repeat kinase 2 (LRRK2) has been linked to familial and sporadic Parkinson's disease. However, it is still unresolved whether LRRK2 in dopaminergic (DAergic) neurons may or may not aggravate the phenotype. We demonstrate that knocking down (KD) the Lrrk gene by RNAi in DAergic neurons untreated or treated with paraquat (PQ) neither affected the number of DAergic clusters, tyrosine hydroxylase (TH) protein levels, lifespan nor locomotor activity when compared to control (i.e. TH/+) flies. KD transgenic Lrrk flies dramatically increased locomotor activity in presence of TH enzyme inhibitor alpha-methyl-para-tyrosine (aMT), whereas no effect on lifespan was observed in both fly lines. Most importantly, KD Lrrk flies had reduced lipid peroxidation (LPO) index alone or in presence of PQ and the antioxidant minocycline (MC, 0.5mM). Taken together, these findings suggest that Lrrk appears unessential for the viability of DAergic neurons in D. melanogaster. Moreover, Lrrk might negatively regulate homeostatic levels of dopamine, thereby dramatically increasing locomotor activity, extending lifespan, and reducing oxidative stress (OS). Our data also indicate that reduced expression of Lrrk in the DAergic neurons of transgenic TH>Lrrk-RNAi/+ flies conferred PQ resistance and absence of neurodegeneration. The present findings support the notion that reduced/suppressed LRRK2 expression might delay or prevent motor symptoms and/or frank Parkinsonism in individuals at risk to suffer autosomal dominant Parkinsonism (AD-P) by blocking OS-induced neurodegenerative processes in the DAergic neurons.


Subject(s)
Drosophila Proteins/antagonists & inhibitors , Parkinsonian Disorders/metabolism , Parkinsonian Disorders/pathology , Protein Serine-Threonine Kinases/antagonists & inhibitors , Animals , Animals, Genetically Modified , Antioxidants/pharmacology , Cell Survival/drug effects , Cell Survival/physiology , Dopamine/metabolism , Dopaminergic Neurons/drug effects , Dopaminergic Neurons/metabolism , Dopaminergic Neurons/pathology , Drosophila Proteins/genetics , Drosophila melanogaster , Female , Minocycline/pharmacology , Motor Activity/drug effects , Motor Activity/physiology , Oxidative Stress/drug effects , Oxidative Stress/physiology , Paraquat , Parkinsonian Disorders/therapy , Protein Serine-Threonine Kinases/genetics , RNA Interference , RNAi Therapeutics , Tyrosine 3-Monooxygenase/antagonists & inhibitors , Tyrosine 3-Monooxygenase/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL